Topiramate in the treatment of highly refractory patients with dravet syndrome

Neuropediatrics

Volumn 37, Issue 6, 2006, Pages 325-329

  Kroll Seger J ^a   Portilla, P ^a   Dulac, O ^a,b,c   Chiron, Catherine ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Dravet syndrome; Highly refractory patients; Topiramate

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID;

AGGRESSION; ANOREXIA; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; DRAVET SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSOMNIA; LANGUAGE DISABILITY; MALE; MYOCLONUS EPILEPSY; NEPHROLITHIASIS; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; WEIGHT REDUCTION;

ANTICONVULSANTS; DIOXOLANES; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; EPILEPSIES, MYOCLONIC; EPILEPSY, TONIC-CLONIC; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SEIZURES, FEBRILE; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 33947575762     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-964867     Document Type: Article

References (20)

1. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330-1337
2. Casse-Perrot C, Wolf M, Dravet C. Neuropsychological aspects of severe myoclonic epilepsy in infancy. Jambaque I, Lassonde M, Dulac O (eds). Neuropsychology of Childhood Epilepsy. New York: Kluwer Academic/Plenum Publishers, 2001: 131-140
3. Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, Lagae L. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol 2004; 19: 516-521
4. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356: 1638-1642
5. Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, d'Athis P, Vincent J, Dulac O, Pons G. Stiripentol in childhood partial epilepsy: a randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 2006; 21: 496-502
6. Claes L, Del Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68: 1327-1332
7. Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 2002; 49: 45-48
8. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey, 2005: 77-88
9. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 1999; 52: 1338-1344
10. FujiwaraT, Sugawara T, Mazaki-Miyazaki E, Takahashi Y, Fukushima K, Watanabe M, Hara K, Morikawa T, Yagi K, Yamakawa K, Inoue Y. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003; 126: 531-546
11. Mikaeloff Y, Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L, Motte J, Bourgeois M, Arzimanoglou A, Dulac O, Chiron C. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003; 53: 225-232
12. Nabbout R, Gennaro E, Dalla BB, Dulac O, Madia F, Bertini E, Capovilla G, Chiron C, Cristofori G, Elia M, Fontana E, Gaggero R, Granata T, Guerrini R, Loi M, La Selva L, Lispi ML, Matricardi A, Romeo A, Tzolas V, Valseriati D, Veggiotti P, Vigevano F, Vallee L, Dagna BF, Bianchi A, Zara F. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology 2003; 60: 1961-1967
13. Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000; 9: 590-594
14. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-356
15. Ritter F, Glauser TA, Elterman RD, Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group. Epilepsia 2000; 41 Suppl 1: S82-S85
16. Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002; 43: 691-696
17. Sugawara T, Mazaki-Miyazaki E, Fukushima K, Shimomura J, Fujiwara T, Hamano S, Inoue Y, Yamakawa K. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology 2002; 58: 1122-1124
18. Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O. Efficacité et tolérance à long terme du stiripentol dans le traitement de l'épilepsie myoclonique sévère du nourrisson (syndrome de Dravet). Arch Pediatr 2002; 9: 1120-1127
19. Tran A, Vauzelle-Kervroedan F, Rey E, Pous G, d'Athis P, Chiron C, Dulac O, Renard F, Olive G. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol 1996; 50: 497-500
20. Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997; 62: 490-504